MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income
$18,263M
(6.60%↑ Y/Y)
Depreciation
$3,045M
(44.72%↑ Y/Y)
Amortization
$2,793M
(16.62%↑ Y/Y)
Share-based compensation
$820M
(7.75%↑ Y/Y)
Other
-$511M
(-0.20%↓ Y/Y)
Noncurrent liabilities
$195M
(497.96%↑ Y/Y)
Income taxes payable
$137M
(-86.61%↓ Y/Y)
Trade accounts
payable
$110M
(-39.56%↓ Y/Y)
Intangible asset
impairment charges
$55M
(41.03%↑ Y/Y)
Net cash provided by
operating activities
$16,472M
(-23.27%↓ Y/Y)
Effect of exchange rate
changes on cash, cash...
$563M
(292.15%↑ Y/Y)
Canceled cashflow
$9,457M
Net increase
(decrease) in cash, cash...
$1,372M
(-78.59%↓ Y/Y)
Canceled cashflow
$15,663M
Other
$3,307M
(133.55%↑ Y/Y)
Accrued and other
current liabilities
-$1,841M
(20.92%↑ Y/Y)
Deferred income taxes
-$1,671M
(-33.79%↓ Y/Y)
Inventories
$1,180M
(41.32%↑ Y/Y)
Accounts receivable
$1,090M
(346.72%↑ Y/Y)
Income from
investments in equity...
$368M
(2528.57%↑ Y/Y)
Proceeds from sales of
securities and other...
$1,678M
(345.09%↑ Y/Y)
Proceeds from issuance of
debt
$13,880M
(285.66%↑ Y/Y)
Proceeds from exercise of
stock options
$92M
(-48.02%↓ Y/Y)
Net cash used in
investing activities
-$13,741M
(-77.67%↓ Y/Y)
Net cash used in
financing activities
-$1,922M
(72.67%↑ Y/Y)
Canceled cashflow
$1,678M
Canceled cashflow
$13,972M
Acquisition of verona pharma
plc, net of cash...
$10,042M
(1246.11%↑ Y/Y)
Capital expenditures
$4,112M
(21.95%↑ Y/Y)
Dividends paid to
stockholders
$8,176M
(4.29%↑ Y/Y)
Purchases of securities
and other...
$1,207M
(132.56%↑ Y/Y)
Other
$58M
(-54.33%↓ Y/Y)
Purchases of treasury
stock
$5,084M
(289.28%↑ Y/Y)
Payments on debt
$2,503M
(94.03%↑ Y/Y)
Other
-$131M
(64.78%↑ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
site-logo-svg
Merck & Co., Inc. (MRK)
site-logo-svg
Merck & Co., Inc. (MRK)